Journal
EUROPEAN HEART JOURNAL
Volume 32, Issue 16, Pages 1968-U34Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehr052
Keywords
Apixaban; Atrial fibrillation; Dabigatran etexilate; Edoxaban; Novel anticoagulants; Rivaroxaban; RE-LY AVERROES; ROCKET AF; ENGAGE-TIMI 48
Categories
Funding
- AstraZeneca
- Bayer HealthCare
- Boehringer Ingelheim
- Sanofi-aventis
- Johnson and Johnson
- Bayer Health Care
- Daichi-Sankyo
- AstraZeneca Pharmaceuticals LP
- Johnson Johnson
- Beckman Coulter, Inc.
- Eli Lilly
- Genentech
- Integrated Therapeutics Group
- Merck Co., Inc.
- Roche Diagnostics Corp.
- sanofi aventis
- Daiichi Sankyo
- Glaxo Smith Kline
- Bristol Myers Squibb
Ask authors/readers for more resources
Anticoagulation for the long-term treatment and prevention of thrombo-embolic diseases as well as for stroke prevention in atrial fibrillation (AF) has been accomplished by vitamin K antagonists for the last half century. Although effective under optimal conditions, the imminent risk of a recurrent event vs. the risk of bleeding due to the narrow therapeutic window, numerous food-and drug interactions, and the need for regular monitoring complicate the long-term use of these drugs and render treatment with these agents complicated. As a result, novel anticoagulants which selectively block key factors in the coagulation cascade are being developed. The efficacy and safety of the direct thrombin inhibitor dabigatran etexilate, as well as of the selective factor Xa inhibitors rivaroxaban and apixaban, have been demonstrated in Phase III trials for stroke prevention in AF and the treatment and secondary prophylaxis of venous thrombo-embolism. This review summarizes the results from recently published pivotal clinical trials and discusses the opportunities as well as uncertainties in the clinical applications of these novel agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available